Por: Ars Technica Science February 01, 2024
Navigate Filter by topic Settings Front page layout Site theme - Feb 1, 2024 12:17 am UTC / The exterior of the headquarters of biotechnology company Biogen in Cambridge, Massachusetts. Biotechnology company Biogen is , its questionable Alzheimer's drug that has floundered on the market since its scandal-plagued regulatory approval in 2021 and brow-raising pricing. On Wednesday, the company announced it had terminated its license for... + full article
MarketWatch USA Business January 31, 2024
The Aduhelm commercial program had been all but dead since 2022, when the Centers for Medicare & Medicaid Services (CMS) declined to offer Medicare coverage for the drug. Biogen had been continuing of Aduhelm, however, as a condition of the Food and Drug Administration’s... + más
Biogen Ends Development of Alzheimer’s Drug Aduhelm | MarketWatch
Biogen Stock: How Biogen Makes Money In 2022 And How They Defied Gravity | Forbes
WPLG Local 10 USA Health January 31, 2024
Biogen will stop developing its Alzheimer’s treatment , a drug once seen as a potential blockbuster before stumbling soon after its launch a couple years ago.The drugmaker said Wednesday that it will end a study of the drug needed for full approval from the Food and Drug... + más
The Boston Globe USA Business July 25, 2023
Biogen said Tuesday that it plans to cut about 1,000 jobs, roughly 11 percent of its global workforce, to lower costs as the Cambridge-based biotech begins to roll out the new Alzheimer’s drug it co-developed and prepares for possible approval of another drug, for depression,... + más
FDA approval of Alzheimer's drug Aduhelm 'rife with irregularities,' House report says | Fox Business
Fox Business USA Business December 30, 2022
Check out what's clicking on FoxBusiness.com A report by two House committees questioned the approval process for an Alzheimer’s drug produced by Biogen. Congressional investigators called the process rife with irregularities.The drug in question is Aduhelm, which was... + más
Biogen to pay $900M to settle allegations of improper physician kickbacks | Fox Business
Los Angeles Times USA Science December 30, 2022
The Food and Drug Administration’s contentious approval of a questionable Alzheimer’s drug took another hit Thursday as congressional investigators called the process “rife with irregularities.” The 18-month investigation by two House committees detailed “atypical... + más
Probe: Alzheimer's drug approval 'rife with irregularities' | ABC News
Probe: Alzheimer's drug approval 'rife with irregularities' | WPLG Local 10
Forbes USA Business October 15, 2022
Getty Images Key Takeaways You may have heard the overwhelmingly positive news for Biogen lately—this stock has been a rare winner during a time of extreme volatility in the stock market due to consistent rate hikes. Biogen Inc. (BIBB) is one of the older global biotech... + más
Biogen to pay $900 million to settle allegations it paid doctors kickbacks to prescribe multiple sclerosis drugs | CNBC
About iurex | Privacy Policy | Disclaimer |